J. Legoux

N. Loménie, A. Lièvre, P. Laurent-Puig, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

A. Lièvre, C. Lepage, C. Lombard-Bohas, 2022, European journal of cancer.

1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

A. Lièvre, C. Lepage, J. Scoazec, 2020 .

Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology)

M. Ychou, J. Duffour, M. Ducreux, 2008 .

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

A. Lièvre, M. Ducreux, C. Lepage, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.

Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy.

V. de Lédinghen, P. Couzigou, Denis Smith, 2006, Gastroenterologie clinique et biologique.

Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).

M. Ychou, J. Duffour, M. Ducreux, 2006, Anticancer research.

HYPERTHYROIDISM ONE MONTH AFTER ACUTE ENTEROCOLITIS DUE TO YERSINIA ENTEROCOLITICA

H. Portier, J. Legoux, D. Spielmann, 1980, The Lancet.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

E. Baudin, C. Lepage, P. Rougier, 2017, European journal of cancer.

Value of microsatellite instability typing in detecting hereditary non-polyposis colorectal cancer. A prospective multicentric study by the Association Aquitaine Gastro.

V. Picot, T. Frebourg, F. Paraf, 2005, Gastroenterologie clinique et biologique.

Prevention of Biliary Stent Occlusion by Ursodeoxycholic Acid plus Norfloxacin

V. de Lédinghen, D. Sautereau, P. Ingrand, 2004, Digestive Diseases and Sciences.

[Lymphocytic colitis, followed by collagenous colitis, associated with mycosis fungoides-type T-cell lymphoma].

D. Gargot, P. Michenet, N. Breteau, 1993, Gastroenterologie clinique et biologique.

[Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients].

X. Causse, J. Legoux, J. Lagasse, 1997, Gastroenterologie clinique et biologique.

Hepato-gastroenterologists and oncologists are complementary in the management of digestive cancers.

C. Lepage, P. Rougier, P. Michel, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The efficacy and safety of duodenal stenting: a prospective multicenter study.

D. Coumaros, T. Ponchon, B. Napoléon, 2007, Endoscopy.

Structural enhancement and video endoscopy: results of a large prospective comparative study.

P. Couzigou, S. Boulogne, J. Legoux, 2009, Gastroenterologie clinique et biologique.

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

B. Chauffert, M. Ychou, P. Rougier, 2010, Gut.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

F. Brunetti, A. Lièvre, C. Lepage, 2020, Annals of surgery.

[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].

P. Michel, J. Raoul, M. Bigard, 1994, Gastroenterologie clinique et biologique.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

T. Conroy, J. Bosset, O. Bouché, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses

C. Lombard-Bohas, P. Ruszniewski, V. Rebours, 2019, Neuroendocrinology.

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.

M. Ychou, P. Rougier, F. Bonnetain, 2010, European journal of cancer.

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

M. Pocard, R. Benamouzig, O. Bouché, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

A. Lièvre, M. Pocard, G. Piessen, 2020, International journal of cancer.

[Chronic renal insufficiency (interstitial nephritis) under mesalazine].

X. Causse, J. Legoux, J. Lagasse, 1998, Gastroenterologie clinique et biologique.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Narrow-band imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trial

T. Ponchon, S. Lecleire, M. Antonietti, 2020, Endoscopy.

Prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin: a multicenter randomized trial.

V. de Lédinghen, D. Sautereau, P. Ingrand, 2000, Digestive diseases and sciences.

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.

T. de Baère, E. Baudin, C. Lepage, 2019, European journal of cancer.

Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.

S. Mathoulin-Pélissier, Y. Bécouarn, C. Bellera, 2011, Clinics and research in hepatology and gastroenterology.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

M. Loriot, J. Thariat, O. Bouché, 2019, Bulletin du cancer.

[Radiation protection of operators during endoscopic retrograde cholangiopancreatography].

X. Causse, J. Germanaud, R. Sabattier, 1993, Gastroenterologie clinique et biologique.

[Obstructive cardiomyopathy of the left ventricle with complete auriculo-ventriculrar block. Therapeutic considerations].

F. Cherrier, J. Legoux, J. Gilgenkrantz, 1968, Archives des maladies du coeur et des vaisseaux.

Oesophageal Squamous Cell Carcinoma Screening Among High-Risk Patients: National Prospective Study of the French Digestive Endoscopy Society (SFED)

T. Barrioz, D. Sautereau, T. Ponchon, 2004 .

Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

P. Rougier, F. Bonnetain, P. Hammel, 2015 .

Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005

M. Ducreux, P. Rougier, D. Peiffert, 2006 .

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Sclerotherapy with or without octreotide for acute variceal bleeding.

D. Heresbach, P. Ingrand, M. Becker, 1995, The New England journal of medicine.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

C. Lombard-Bohas, A. Bertaut, F. Ghiringhelli, 2020, Cancers.

[Extra-hepatic manifestations of viral hepatitis].

X. Causse, J. Germanaud, J. Legoux, 1995, La Revue du praticien.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.